<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01911676</url>
  </required_header>
  <id_info>
    <org_study_id>1303011716</org_study_id>
    <secondary_id>4UH3TR000960-02</secondary_id>
    <nct_id>NCT01911676</nct_id>
  </id_info>
  <brief_title>Translational Neuroscience Optimization of GlyT1 Inhibitor</brief_title>
  <acronym>NCATS</acronym>
  <official_title>Translational Neuroscience Optimization of GlyT1 Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, randomized, double-blind, placebo-controlled, cross-over POC study of
      stable patients with Schizophrenia or Schizoaffective disorder. The primary objective of this
      study is to test the efficacy of treatment with one of two does of a glycine transporter
      inhibitor (GlyT1I) combined with cognitive remediation to enhavce cognitive function.
      Subjects will be randomized to one of two doses of the glycine transporter inhibitor (GlyT1I)
      and placebo twice daily in addition to their antipsychotic medication for 2 treatment
      periods, each lasting a minimum of 5 weeks. Treatment periods will be separated by a washout
      period lasting approximately 3 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of PF-03463275 on Specific Cognitive Domains</measure>
    <time_frame>Change from baseline in cognitive measures at approximately 5 weeks</time_frame>
    <description>To test the efficacy of PF-03463275 on cognitive test performance specifically, with change in specific cognitive domains including verbal and visual learning and short-term/working memory examined as exploratory analyses.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alteration in symptom domain scores and event related potentials (ERPs) with PF-03463275</measure>
    <time_frame>Change from Baseline at approximately 1 week</time_frame>
    <description>To determine whether PF-03463275 impacts symptom domain scores and visual event related potentials (ERPs), analogous to long-term potentiation (LTP) with PF-03463275 treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Cognitive Impairments Associated With Schizophrenia</condition>
  <arm_group>
    <arm_group_label>PF-03463275 Active Dose #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active dose between 40mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-03463275 Active Dose #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active dose between 60mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo- no active dose of PF-03463275.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03463275</intervention_name>
    <arm_group_label>PF-03463275 Active Dose #1</arm_group_label>
    <arm_group_label>PF-03463275 Active Dose #2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) Males or females 21 to 65 years of age (inclusive).

          -  2) Diagnosis of Schizophrenia or Schizoaffective Disorder

          -  3) Able to provide written informed consent.

          -  4) Only CYP2D6 extensive metabolizers.

        Exclusion Criteria:

          -  1) No ongoing acute medical issues

          -  2) Clinically significant ECG abnormality

          -  3) Blood donation within eight weeks of the start of the study

          -  4) Current treatment with Clozapine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepak C D'Souza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Connecticut Mental Health Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 10, 2013</study_first_submitted>
  <study_first_submitted_qc>July 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2013</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

